Malundo, 1,215 patient HCQ late treatment study: 24% higher mortality [p=0.32] https://c19p.org/malundo
copied to clipboard
Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines
et al., IJID Regions, doi:10.1016/j.ijregi.2022.07.009
Retrospective 1,215 hospitalized patients in the Phillipines, showing no significant difference in outcomes with remdesivir or HCQ use in unadjusted results subject to confounding by indication.
|
risk of death, 24.4% higher, RR 1.24, p = 0.32, treatment 20 of 90 (22.2%), control 201 of 1,125 (17.9%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Malundo et al., 7/14/2022, retrospective, Philippines, peer-reviewed, 16 authors, study period 12 March, 2021 - 9 September, 2021.
Contact:
agmalundo@up.edu.ph, annaflormalundo@gmail.com.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.